Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06419231 · ClinicalTrials.gov registry record · NA

Effectiveness of a Butyrate Formulation and Butyrate + Polyphenol Formulation on Gut Health, Permeability and Associated Symptoms

A NA study, sponsored by Supplement Formulators.

Completed
Registry status
NA
Development phase
143
Enrollment target

NCT06419231: Completed NA study, sponsored by Supplement Formulators.

NCT06419231 is a NA study that has completed, run by Supplement Formulators. The registered enrollment target is 143 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06419231, a NA study, has completed, sponsored by Supplement Formulators.

COMPLETED
Registry status
NA
Development phase
143 participants
Enrollment target

Study Summary

The purpose of this study is the assess the effectiveness and safety of a Butyrate formulation and a Butyrate + Polyphenol formulation on gut health, permeability and associated symptoms

Primary Outcome

Assessment of the median change in the results of the Gut Microbiome from baseline.

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Butyrate + Polyphenol Formulation
  • DIETARY_SUPPLEMENT Butyrate Formulation

Trial Details

FieldValue
Enrollment Target 143 participants
Start Date 2023-10-31
Est. Completion 2025-06-18
Phase NA
Supplement Formulators

14 total trials

What the finished NCT06419231 record still lists

NCT06419231 is an interventional study that assigns participants to a tested intervention. The registered 143 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT06419231 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06419231 about?

NCT06419231 is a clinical study titled "Effectiveness of a Butyrate Formulation and Butyrate + Polyphenol Formulation on Gut Health, Permeability and Associated Symptoms". The purpose of this study is the assess the effectiveness and safety of a Butyrate formulation and a Butyrate + Polyphenol formulation on gut health, permeability and associated symptoms

What is the current status of trial NCT06419231?

This trial is currently completed. It is a NA study. The enrollment target is 143 participants. The study started on 2023-10-31. Estimated completion is 2025-06-18.

What interventions are being tested in trial NCT06419231?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Butyrate + Polyphenol Formulation (DIETARY_SUPPLEMENT), Butyrate Formulation (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06419231?

This trial is sponsored by Supplement Formulators, which has 14 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06419231's enrollment target sits among peer trials

143 711th of 2000 higher than 1,290 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01861106 · 144 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations

  • NCT03482245 · 144 participants · NA

    The Role of Circadian Clock Proteins in Innate and Adaptive Immunity

  • NCT03504683 · 144 participants · NA

    MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes

  • NCT03905603 · 144 participants · Early Phase 1

    Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06419231, the US trial registry maintained by the National Library of Medicine. NCT06419231 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.